4.7 Article

Suppressed renoprotective purines in COVID-19 patients with acute kidney injury

期刊

SCIENTIFIC REPORTS
卷 12, 期 1, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41598-022-22349-z

关键词

-

资金

  1. NIH [DK091190, HL109002, DK079307, K23 HL139987]
  2. UPMC
  3. UPMC Immune Transplant and Therapy Center
  4. University of Pittsburgh Clinical and Translational Science Institute
  5. Gilead Sciences
  6. Karius, Inc.
  7. Small Molecule Biomarker Core (NIH) [S10ODO28540]

向作者/读者索取更多资源

Patients with COVID-19 and acute kidney injury (AKI) have significantly reduced levels of renoprotective purines in their urine, suggesting an imbalance in these purines may contribute to AKI. Pharmacotherapy targeted at restoring renoprotective purine levels may attenuate the risk of AKI in susceptible patients with COVID-19.
Acute kidney injury (AKI) is common in patients hospitalized for COVID-19, complicating their clinical course and contributing to worse outcomes. Animal studies show that adenosine, inosine and guanosine protect the kidney against some types of AKI. However, until now there was no evidence in patients supporting the possibility that abnormally low kidney levels of adenosine, inosine and guanosine contribute to AKI. Here, we addressed the question as to whether these renoprotective purines are altered in the urine of COVID-19 patients with AKI. Purines were measured by employing ultra-high-performance liquid chromatography-tandem mass spectrometry with stable-isotope-labeled internal standards for each purine of interest. Compared with COVID-19 patients without AKI (n = 23), COVID-19 patients with AKI (n = 20) had significantly lower urine levels of adenosine (P < 0.0001), inosine (P = 0.0008), and guanosine (P = 0.0008) (medians reduced by 85%, 48% and 61%, respectively) and lower levels (P = 0.0003; median reduced by 67%) of the 2nd messenger for A(2A) and A(2B) adenosine receptors, i.e., 3',5'-cAMP. Moreover, in COVID-19 patients with AKI, urine levels of 8-aminoguanine (endogenous inhibitor of inosine and guanosine metabolism) were nearly abolished (P < 0.0001). In contrast, the upstream precursors of renoprotective purines, namely 5'-AMP and 5'-GMP, were not significantly altered in COVID-19 patients with AKI, suggesting defective conversion of these precursors by CD73 (converts 5'-AMP to adenosine and 5'-GMP to guanosine). These findings imply that an imbalance in renoprotective purines may contribute to AKI in COVID-19 patients and that pharmacotherapy targeted to restore levels of renoprotective purines may attenuate the risk of AKI in susceptible patients with COVID-19.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据